Track topics on Twitter Track topics that are important to you
Arch Biopartners (TSXV:ARCH;OTCQB:ACHFF) today provided an update on the general results from toxicology and pharmacology studies evaluating Metablok, the Company’s lead drug candidate for treating acute kidney injury. As quoted in the press release: In seven day studies involving rodents and another larger animal species, there were no significant drug-related side effects in the toxicology … Continued
The post Arch Biopartners Provides Toxicology Update for Metablok appeared first on Investing News Network.
Original Article: Arch Biopartners Provides Toxicology Update for MetablokNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...